.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Dr. Young-In Ko

Munich / DE

GSK Germany

Industrial Speaker

30/03/2023
Industrial Talk
Welcome & Introduction

Speaker

28/03/2023
Poster
P 309
Respiratory Syncytial Virus (RSV) prefusion F protein candidate vaccine (RSVPreF3 OA) is efficacious in adults ≥ 60 years of age (YOA)
Clinical virology, Vaccines

Further involvements

28/03/2023
Poster
P 308
Broad neutralization against contemporary and antigenically-distant respiratory syncytial virus (RSV) strains elicited by the vaccine candidate RSVPreF3-AS01
Host cell factors and modulation, Vaccines
28/03/2023
Poster
P 309
Respiratory Syncytial Virus (RSV) prefusion F protein candidate vaccine (RSVPreF3 OA) is efficacious in adults ≥ 60 years of age (YOA)
Clinical virology, Vaccines